The termination of a license agreement often suggests a strategic shift or a setback in development for a biotech company. This could potentially affect Quince Therapeutics' product pipeline and market expectations, leading to a negative short-term impact on the stock price. However, without details on the specifics of the agreement or the reasons for termination, the long-term impact remains uncertain.